Annalisa Meola is a prominent inventor based in Rome, Italy. She has made significant contributions to the field of vaccine technology, particularly through her innovative work on adenoviral vectors. With a total of 2 patents, her research focuses on developing effective methods for delivering immunogens to enhance immune responses.

Latest Patents

Annalisa's latest patents include the development of chimpanzee adenovirus vaccine carriers. This invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses. It outlines methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also details compositions and methods suitable for delivering and expressing transgenes encoding immunogens, which are crucial for eliciting a boosted immune response. Furthermore, it provides methods for generating clinical-grade vector stocks suitable for human use. In particular, the invention contemplates using vectors that encode tumor-associated antigens in vaccines and pharmaceutical compositions aimed at preventing and treating cancer.

Career Highlights

Annalisa has worked with notable organizations such as Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A. and MSD Italia S.r.l. Her work in these institutions has allowed her to advance her research and contribute to the scientific community.

Collaborations

Annalisa has collaborated with esteemed colleagues, including Stefano Colloca and Alfredo Nicosia. These partnerships have further enriched her research and innovation in the field of vaccine development.

Conclusion

Annalisa Meola's contributions to vaccine technology through her innovative patents and collaborations highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in immunology and cancer treatment.

This text is generated by artificial intelligence and may not be accurate.